Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497706 | 0.86 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2503430 | 0.77 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2505339 | 0.77 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3809729 | 0.75 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2497708 | 0.75 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2502872 | 0.73 | PTGDR2 (0.55) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL153274 | 0.73 | PTGDR2 (0.61) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3629690 | 0.72 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1270654 | 0.72 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL153039 | 0.71 | PTGDR2 (0.70) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010042652-A2 | HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |